These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38156615)
21. Reduction of alcohol drinking of alcohol-preferring (P) and high-alcohol drinking (HAD1) rats by targeting phosphodiesterase-4 (PDE4). Franklin KM; Hauser SR; Lasek AW; McClintick J; Ding ZM; McBride WJ; Bell RL Psychopharmacology (Berl); 2015 Jul; 232(13):2251-62. PubMed ID: 25585681 [TBL] [Abstract][Full Text] [Related]
22. Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease. Liu J; Liu L; Zheng L; Feng KW; Wang HT; Xu JP; Zhou ZZ Eur J Med Chem; 2022 Aug; 238():114503. PubMed ID: 35689855 [TBL] [Abstract][Full Text] [Related]
23. Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease. Vatsalya V; Royer AJ; Jha SK; Parthasarathy R; Tiwari H; Feng W; Ramchandani VA; Kirpich IA; McClain CJ Adv Clin Chem; 2023; 114():83-108. PubMed ID: 37268335 [TBL] [Abstract][Full Text] [Related]
24. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690 [TBL] [Abstract][Full Text] [Related]
25. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects. Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916 [TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions. Parikh N; Chakraborti AK Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614 [TBL] [Abstract][Full Text] [Related]
27. Management of alcohol use disorder in patients with chronic liver disease. Mellinger JL; Fernandez AC; Winder GS Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37314739 [TBL] [Abstract][Full Text] [Related]
28. Rodent Models of Alcoholic Liver Disease: Role of Binge Ethanol Administration. Ghosh Dastidar S; Warner JB; Warner DR; McClain CJ; Kirpich IA Biomolecules; 2018 Jan; 8(1):. PubMed ID: 29342874 [TBL] [Abstract][Full Text] [Related]
29. Multi-omics integration reveals the hepatoprotective mechanisms of ursolic acid intake against chronic alcohol consumption. Yan X; Liu X; Wang Y; Ren X; Ma J; Song R; Wang X; Dong Y; Fan Q; Wei J; Yu A; Sui H; She G Eur J Nutr; 2022 Feb; 61(1):115-126. PubMed ID: 34215920 [TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy for alcoholic patients with alcoholic liver disease. Vuittonet CL; Halse M; Leggio L; Fricchione SB; Brickley M; Haass-Koffler CL; Tavares T; Swift RM; Kenna GA Am J Health Syst Pharm; 2014 Aug; 71(15):1265-76. PubMed ID: 25027533 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma Expression. Malnassy G; Keating CR; Gad S; Bridgeman B; Perera A; Hou W; Cotler SJ; Ding X; Choudhry M; Sun Z; Koleske AJ; Qiu W Cell Mol Gastroenterol Hepatol; 2023; 16(5):685-709. PubMed ID: 37460041 [TBL] [Abstract][Full Text] [Related]
32. Apremilast Alters Behavioral Responses to Ethanol in Mice: I. Reduced Consumption and Preference. Blednov YA; Da Costa AJ; Tarbox T; Ponomareva O; Messing RO; Harris RA Alcohol Clin Exp Res; 2018 May; 42(5):926-938. PubMed ID: 29469962 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. Li H; Fan C; Feng C; Wu Y; Lu H; He P; Yang X; Zhu F; Qi Q; Gao Y; Zuo J; Tang W Br J Pharmacol; 2019 Jul; 176(13):2209-2226. PubMed ID: 30883697 [TBL] [Abstract][Full Text] [Related]
34. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia. Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956 [TBL] [Abstract][Full Text] [Related]
35. Chronic alcohol-induced liver injury correlates with memory deficits: Role for neuroinflammation. King JA; Nephew BC; Choudhury A; Poirier GL; Lim A; Mandrekar P Alcohol; 2020 Mar; 83():75-81. PubMed ID: 31398460 [TBL] [Abstract][Full Text] [Related]
36. Improving alcohol treatment engagement using integrated behavioral interventions in alcohol-associated liver disease: A randomized pilot trial. Mellinger JL; Medley S; Kidwell KM; Asefah H; Winder GS; Fernandez AC; Lok ASF; Blow F Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708435 [TBL] [Abstract][Full Text] [Related]
37. The effects of Gentiana dahurica Fisch on alcoholic liver disease revealed by RNA sequencing. Cao H; Xi S; He W; Ma X; Liu L; Xu J; Zhang K; Li Y; Jin L J Ethnopharmacol; 2021 Oct; 279():113422. PubMed ID: 33007391 [TBL] [Abstract][Full Text] [Related]
38. Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases. Liu H; Wang Q; Huang Y; Deng J; Xie X; Zhu J; Yuan Y; He YM; Huang YY; Luo HB; He X Eur J Med Chem; 2022 Nov; 242():114631. PubMed ID: 35985255 [TBL] [Abstract][Full Text] [Related]